Filing summary
Entity and period: The supplied filing is NantKwest, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed March 13, 2019. This does not match the request metadata naming ImmunityBio, Inc.; confirm the issuer before relying on this summary. The filing reports annual results and includes unaudited quarterly data, including fourth-quarter 2018.
Business context
NantKwest was a clinical-stage immunotherapy company developing allogeneic natural killer cell therapies for cancer and, longer term, viral diseases. Its programs included aNK, antibody-enhanced haNK, CAR-engineered taNK, and combined t-haNK candidates. It had no approved products and generated no product-sales revenue; reported revenue came mainly from non-clinical cell-line and intellectual-property licenses.
Financial performance and liquidity
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $47,000 | $45,000 |
| Research and development expense | $55.7 million | $42.0 million |
| Selling, general and administrative expense | $42.7 million | $57.1 million |
| Total operating expenses | $98.4 million | $99.2 million |
| Net loss | $96.2 million | $96.4 million |
| Net loss per share | $1.22 | $1.20 |
| Cash used in operating activities | $63.4 million | $48.8 million |
At year-end, cash and cash equivalents were $16.8 million and marketable debt securities were $63.0 million; working capital was $61.5 million. Total assets were $182.0 million, total liabilities $35.9 million, and stockholders’ equity $146.0 million. Financing obligations were approximately $6.9 million including current and long-term portions. The filing gives no meaningful gross-margin figure for this pre-commercial company.
FY 2018 net loss was nearly unchanged from 2017, while operating cash use increased by $14.6 million. R&D expense rose $13.7 million, mainly with increased manufacturing, laboratory, clinical activity and staffing. SG&A fell $14.4 million, primarily because stock-based compensation declined, including completion of vesting on certain CEO awards. Stock-based compensation totaled $23.4 million, down from $37.0 million.
Fourth-quarter 2018 revenue was $7,000, operating expenses were $17.7 million, and net loss was $17.3 million, compared with fourth-quarter 2017 revenue of $12,000 and net loss of $24.5 million.
Material developments, outlook and risks
- The company completed construction and preparation of its El Segundo commercial-scale GMP facility and transferred manufacturing operations there; it expected clinical production at the facility in early 2019. It also reported cryopreserved haNK supply and plans to introduce larger-capacity bioreactor technology.
- Management expected existing cash, investments and potential affiliate borrowing to fund operations for at least 12 months after the financial statements’ issuance. This liquidity assessment depended on the CEO’s stated intent and ability to provide affiliate funding; the company had no committed external funding source and anticipated needing substantial additional capital.
- For 2019, NantKwest planned first-in-human trials for CD19.t-haNK and PD-L1.t-haNK and continued development of haNK combination studies, including a Merkel cell carcinoma trial with N-803 and avelumab. These were plans, not assured milestones or approvals.
- Early clinical findings were preliminary and based on small patient groups. The filing reported no treatment-related serious adverse events in certain haNK combination experience, but efficacy remained unestablished; haNK efficacy data from its single-agent first-in-human study were pending at filing.
- A proposed $12.0 million securities-litigation settlement was preliminarily approved in January 2019, subject to final court approval. NantKwest’s share was $1.2 million and insurers were to fund $10.8 million; the settlement was paid into a fund in January 2019. Final approval was scheduled for April 29, 2019.
- Key risks include continued losses and cash burn, clinical and regulatory failure or delay, manufacturing scale-up and product comparability, dependence on related-party services and supplies, intellectual-property challenges, competition, reimbursement uncertainty, and the possibility that additional financing may dilute shareholders or require program reductions.
- The CEO and affiliated entities controlled approximately 59.2% of common stock at year-end. The company identified itself as a Nasdaq “controlled company” and relied on related-party arrangements. Management concluded disclosure controls and internal control over financial reporting were effective; the independent auditor did not attest to internal-control effectiveness.
Most important facts for investors to verify
- Confirm that NantKwest—not ImmunityBio—is the intended issuer and that the intended period is FY 2018, with Q4 figures used only as supplemental quarterly data.
- Check the latest cash, marketable securities, operating cash burn and financing support after December 31, 2018, including whether affiliate borrowing was available on acceptable terms.
- Review subsequent trial enrollment, safety and efficacy results, FDA status, and whether planned 2019 trial timelines were achieved.
- Confirm final court approval and ultimate company-funded cost of the securities-litigation settlement.
- Assess related-party agreements, governance and control concentration, and the accounting and operational readiness of the new manufacturing facility.